• Profile
Close

Sacubitril/valsartan vs angiotensin receptor inhibition in heart failure: A real‐world study in Taiwan

ESC Heart Failure Jul 31, 2020

Chang PC, Wang CL, Hsiao FC, et al. - Using data from the Chang Gung Research Database, researchers compared angiotensin receptor–neprilysin inhibitor therapy vs angiotensin receptor blocker (ARB) therapy in terms of efficacy for cardiovascular outcomes in patients experiencing heart failure (HF) with reduced ejection fraction. They performed 1:1 propensity score matching based on age, gender, and baseline left ventricular ejection fraction. Findings demonstrated the superiority of sacubitril/valsartan over ARB therapy in decreasing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular mortality in patients suffering from HF with reduced ejection fraction.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay